SPY329.17+0.38 0.12%
DIA267.53+0.81 0.30%
IXIC10,907.66+4.86 0.04%

ContraFect Reports First Patient Dosed In Pivotal Phase 3 DISRUPT Study Of Exebacase As Treatment For Staph Aureus Bacteremia

Benzinga · -